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Abstract
Introduction: HIV prevention strategies are moving towards reducing plasma HIV RNA viral load in all HIV-positive persons,
including those undiagnosed, treatment naı̈ve, on or off antiretroviral therapy. A proxy population for those undiagnosed are
patients that present late to care with advanced HIV. The objectives of this analysis are to examine factors associated with
patients presenting with advanced HIV, and establish rates of treatment interruption and modification after initiating ART.
Methods: We deterministically linked records from the Australian HIV Observational Database to the Australian National HIV
Registry to obtain information related to HIV diagnosis. Logistic regression was used to identify factors associated with advanced
HIV diagnosis. We used survival methods to evaluate rates of ART initiation by diagnosis CD4 count strata and by calendar year of
HIV diagnosis. Cox models were used to determine hazard of first ART treatment interruption (duration 30 days) and time to
first major ART modification.
Results: Factors associated (pB0.05) with increased odds of advanced HIV diagnosis were sex, older age, heterosexual mode of
HIV exposure, born overseas and ruralregional care setting. Earlier initiation of ART occurred at higher rates in later periods
(20072012) in all diagnosis CD4 count groups. We found an 83% (69, 91%) reduction in the hazard of first treatment in-
terruption comparing 20072012 versus 19962001 (pB0.001), and no difference in ART modification for patients diagnosed
with advanced HIV.
Conclusions: Recent HIV diagnoses are initiating therapy earlier in all diagnosis CD4 cell count groups, potentially lowering
community viral load compared to earlier time periods.We found a marked reduction in the hazard of first treatment interruption,
and found no difference in rates of major modification to ART by HIV presentation status in recent periods.
Keywords: combination antiretroviral therapy; late diagnosis; advanced HIV diagnosis; treatment interruption; treatment
modification.
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Introduction
Antiretroviral therapy (ART) is considered to be a life-long
viable means to control HIV in patients and populations [1].
The introduction of fixed dose, once-a-day dosing and later
generation antiretrovirals with more potency and fewer side
effects has reduced treatment complexity, toxicity and ame-
liorated long-term adherence concerns. A developing body
of evidence also suggests that initiating ART at higher CD4
cell counts translates into improved individual clinical out-
comes [2], as well as a broader population-level reduction
in community viral load (cVL) facilitating a reduction in HIV
incidence [38]. In response, HIV prevention strategies are
moving towards reducing plasma HIV RNA viral load in all
HIV-positive persons, including those undiagnosed, treatment
naı̈ve, on or off ART.
In Australia, the rate of new HIV diagnoses has been
steadily increasing since 1999 [9]. Of these newly diagnosed
cases, the proportion presenting with later stage HIV disease
has remained relatively stable over time [9]. Applying the
European consensus definition for late presentation with
HIV [10], approximately 40% of cases present late to care
with CD4 cell count B350 cells/mL, and approximately 20%
are diagnosed with advanced HIV disease (CD4 cell count
B200 cells/mL). People with undiagnosed HIV for a large
period of time might typically present late to care with
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advanced HIV and, by extension, might have been a higher
risk of onwards transmission during their undiagnosed period
contributing to an increasing incidence of HIV [11,12]. Iden-
tifying the characteristics of people who are at higher risk for
presenting late to care with HIV and evaluating their shorter-
term treatment experience might help inform clinical care
practice for this large proportion of diagnoses.
The objectives of this analysis are to describe the popu-
lation of patients presenting very late to care with HIV in
Australia, identify patient characteristic correlates of these
diagnoses, determine rates of antiretroviral therapy initiation
from time of diagnosis and evaluate rates of treatment
interruptions and major modifications to first-line ART.
Methods
Study population
The analysis population is based on patients recruited to the
Australian HIV Observational Database (AHOD) by 31 March
2013. AHOD is an on-going longitudinal cohort study of HIV-
positive patients in Australia. A comprehensive description
has been previously described elsewhere [13,14]. Briefly,
AHOD data are collected from 29 sites throughout Australia
including hospital tertiary referral centres, sexual health clin-
ics and general medical practices with a special interest in
HIV. Written informed consent is obtained at time of cohort
enrolment. The relevant Human Research Ethics Commit-
tees (HREC) has granted ethical approval for AHOD to all
participating sites.
Data collection for AHOD commenced in 1999 and retro-
spective clinical data collected prior to the establishment of
the cohort are provided where available. Data are transferred
electronically to the Kirby Institute and subjected to quality
control and quality assurance procedures. Data for AHOD
are collected every six months on a core set of demographic
and clinical variables, including sex, age, HIV exposure,
hepatitis B virus surface antigen (HBsAg), hepatitis C virus
antibody (HCV), CD4 and CD8 cell counts, plasma HIV viral
load, antiretroviral treatment history, AIDS illnesses and date
and cause of death.
Data linkage
Date of HIV diagnosis and full CD4 cell count histories are
collected in AHOD routinely where available. Due to recall
bias and missing information, some of these data cannot be
validated at the site data source level. To validate and further
complete missing HIV diagnosis information in AHOD, data
were linked to the Australian National HIV Registry (NHR) to
obtain the date of the first HIV-positive test and correspond-
ing CD4 cell count. The NHR was established in 1990 and
incorporates all Australian state and territory health depart-
ment records of HIV diagnoses from 1985 when HIV antibody
testing first became available in Australia. A positive HIV
antibody result is a notifiable event and requires reporting to
state/territory health authorities. Information collected for
each notification includes basic demographic and clinical
characteristics [15]. The databases were linked using a two-
pass, deterministic, one-to-many join (AHOD-to-NHR) data
linkage procedure. The first pass joined the databases using
an exact match on a unique identifier consisting of the
concatenation of state/territory, sex, name code and date of
birth information. The second pass took those not matched
from pass one and removed the state/territory identifier
from the linkage-key identifier. After pass two, any un-
matched records were excluded from the analysis.
Approval to link AHOD and NHR was obtained by all
Australian jurisdictional health departments and was re-
viewed and approved for ethical considerations by the
New South Wales Population and Health Services Research
Ethics Committee.
Definitions & outcomes
To determine HIV presentation status, each participant had
to have recorded a CD4 cell count at HIV diagnosis in the
NHR. We defined presentation with advanced HIV disease as
diagnosis with CD4 cell count B200 cells/mL or AIDS illness
within six months of HIV diagnosis. We restricted our analysis
population to AHOD participants who were diagnosed with
HIV in the combination antiretroviral therapy era, defined as
HIV diagnosis made after the 1 January 1996.
Initiation of first-line ART was the first recorded instance
of the concurrent usage of ]3 antiretrovirals for a duration
7 days. Of those participants who initiated ART, we estab-
lished a broad timing of initiation group based on CD4 cell
count at the time of diagnosis and CD4 at the time of ART
initiation. Here, we are comparing treatment-related out-
comes of those diagnosed with advanced HIV against those
diagnosed with a higher CD4 cell count. We further refined
the comparator arm by dichotomizing on CD4 cell count at
the time of ART initiation. We categorized each participant
into one of three groups,
1) Advanced HIV diagnosis: CD4 cell count at HIV diagnosis
B200 cells/mL or AIDS illness within six months of
diagnosis.
2) CD4ART B350 cells/mL: CD4 cell count at HIV diagnosis
350 cells/mL and CD4 cell count at ART initiation
B350 cells/mL.
3) CD4ART ]350 cells/mL: CD4 cell count at HIV diagnosis
350 cells/mL and CD4 cell count at ART initiation
]350 cells/mL.
We defined the time to first treatment interruption as the
first instance of ceasing ART continuously for 30 days. We
defined the time to first major modification of ART as the
removal, addition or switch of an antiretroviral class from
the original ART regimen. Within class substitutions were
not counted in our definition of a major ART modification.
For analyses examining time to first treatment interrup-
tion or first treatment modification, we wanted to directly
compare treatment-related outcomes in non-late HIV diag-
noses. Therefore, using the above definition, AHOD partici-
pants who were diagnosed with a CD4 cell count 200350
cells/mL were excluded from the main analysis (n179).
However, as a sensitivity analysis, we varied the definition
to capture theses late presenters, defined as diagnosis CD4
cell count B350 cells/mL or AIDS illness with six months of
diagnosis.




We tabulated patient characteristics stratified by CD4 cell count
at time of HIV diagnosis (0200, 201350, 350 cells/mL).
We assessed factors associated with advanced HIV diagnosis
using logistic regression. We determined an adjusted odds
ratio (aOR) for each factor using an a priori model adjusting
for sex, age, mode of exposure, continental region of birth,
hepatitis B co-infection, hepatitis C co-infection, primary care
setting, regional care setting and year of HIV diagnosis.
We assessed the statistical significance of each factor using
a Wald test.
We used KaplanMeier survival methods to evaluate
differences in rates of ART initiation stratified by CD4 cell
at diagnosis (0200, 201350, 351500, 500 cells/mL). To
evaluate recent trends in ART initiation by CD4 cell count
at diagnosis, we used an adjusted Cox proportional hazards
model to formally test the interaction between calendar year
of HIV diagnosis (groups: 19962000, 20012006, 20072012)
and CD4 cell count at HIV diagnosis. The calendar year pe-
riods were broadly selected based on the availability of
newer generation antiretrovirals (e.g. atripla) and alongside
major changes in HIV treatment management guidelines
(e.g. CD4 initiation threshold moving to B250 cells/mL).
Further details on the evolution of the Australian HIV treat-
ment guidelines can be found in Hoy and Lewin [16].
We used Cox proportional hazard models to evaluate HIV
presentation status on the time to first ART interruption
(30 days) and the time to first major modification of ART.
All models were adjusted for age, sex, mode of HIV exposure
and primary care setting. Patients were considered lost-to-
follow-up if they had not been seen at the clinic for 12
months. We censored patients at their last follow-up visit or
at the administrative date of five years duration of ART,
whichever occurred first.
Statistical significance was assessed at the a-level0.05
level unless otherwise stated. All statistical calculations were
performed using SAS Version 9.3.
Results
A total of 2982 (83%) out of 3608 unique AHOD patient
identifiers were matched to records from the NHR. Of the
linked records, a total of 1599 were diagnosed HIV-positive
after 1 January 1996. A further 397 participants were ex-
cluded from the analysis due to missing diagnosis CD4 cell
count. A grand total of 1202 were eligible for analysis. The
linked NHR diagnosis date is more specific and an improve-
ment on corresponding AHOD records as shown by compar-
ing the frequency distribution of each component of the HIV
diagnosis date (day, month, year), Supplementary Figure 1.
A total of 528 (43%) diagnosis CD4 cell count records were
completed (or gained) after the data linkage procedure.
Supplementary Figure 2 demonstrates almost perfect con-
cordance of available AHOD CD4 cell count data with those
captured by the NHR. Patient characteristics of those linked/
not-linked or included/excluded in the analysis are presented
in Supplementary Table 1.
The proportion of participants in our analysis of population
diagnosed with advanced HIV was 0.21 (0.18, 0.23). The
proportion of participants diagnosed with late HIV was 0.35
(0.33, 0.38). Analysis of population-patient characteristics is
shown in Table 1. Univariate and multivariable aORs for fac-
tors associated with advanced HIV diagnoses are presented
in Table 2. Factors associated with diagnosis of advanced
HIV include: sex, female aOR0.50 (0.26, 0.98) relative to
male; older age, 50 years aOR4.91 (2.74, 8.76) relative
to B30 years old; mode of HIV exposure, heterosexual
aOR2.04 (1.38, 3.02) or other (blood products, needle
sticks, etc.) aOR2.05 (1.08, 3.86) compared to men who
have sex with men (MSM); born in high HIV-prevalence
countries, Africa aOR3.87 (1.49, 10.1) and Asia aOR2.57
(1.44, 4.58) relative to those born in Australia; partici-
pants receiving care from a hospital tertiary referral clinic,
aOR2.88 (1.57, 5.30) compared to those receiving care
at a sexual health clinic. We found no interactions between
factors studied with year of diagnosis. This implies no large
temporal changes in factors associated with advanced HIV
diagnoses over time. Sensitivity analyses of aORs for late diag-
nosis are shown in Supplementary Table 2 and qualitatively
similar results were found.
Rates of ART initiation differed by diagnosis CD4 cell
count strata, pB0.0001 and year of HIV diagnosis, pB0.0001
(Figure 1). The adjusted model interaction term between
diagnosis CD4 cell count strata and year of HIV diagnosis was
insignificant (p0.08), indicating the ART initiation patterns
for year of HIV diagnosis did not differ within each diagnosis
CD4 cell count stratum (Figure 1). The majority of participants
diagnosed with a CD4 count B500 cells/mL initiated ART
within five years of their HIV diagnosis. For recent HIV diag-
noses (20072012) and using KaplanMeier estimates, the
time for 50% of participants initiating ART by diagnosis CD4
cell count strata were 1 (1, 2) month, 6 (4, 14) months,
14 (12, 24) months and 28 (23, 43) months for groups 0200,
201350, 351500 and 500 cells/mL, respectively.
The estimated hazard ratios for time to first ART treatment
interruption stratified by HIV presentation status are pre-
sented in Table 3.We found an 83% (69, 91%) reduction in the
hazard of first treatment interruption in recent time periods
(20072012) relative to earlier time periods (19962000),
pB0.001. We demonstrate a higher hazard of treatment in-
terruption in those who initiated ART therapy with a higher
CD4 cell count aHR1.96 (1.22, 3.20) compared to those that
started with a lower count (CD4B350 cells/mL), pB0.001.
We found no difference in hazard of treatment interrup-
tion in those diagnosed with advanced HIV (and initiated
ART) compared to those who started with a CD4 cell count
B350 cells/mL. An interaction term between HIV presentation
status and calendar year was non-significant (p0.93), indicat-
ing that broad patterns of treatment interruption hazards
for HIV presentation status are similar within each time
period. Similar results were found comparing late diagnosis
to CD4ART B350 cells/mL or CD4ART ]350 cells/mL groups
(Supplementary Table 3).
The hazard of a first major modification to ART by HIV
presentation status is presented in Table 4. An interaction
term between HIV presentation status and recent time period
was statistically significant, p0.03.We found no differences
in ART modification hazard for HIV presentation status in
year of ART initiation groups 20012006 and 20072012.
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In the time period 19962000, the rate of modifying ART
regimens in advanced HIV diagnosis and those that started
ART with a CD4 ]350 cells/mL were higher than those that
initiated ART with a lower CD4 count, 4.13 (1.28, 13.34) and
2.46 (0.75, 8.07) respectively. Again, comparing late diagnosis
to the other groups we found similar results (Supplementary
Table 4).
Discussion
In our study, we used a data linkage methodology to as-
certain the date of HIV diagnosis and CD4 cell count at
diagnosis for each participant in AHOD. We used these data
to estimate the proportion of participants diagnosed with
advanced HIV in AHOD and identify associations of increased
odds of advanced HIV diagnosis. To our knowledge, for the
first time using Australian data, we have characterized the
rates of ART initiation from first HIV-positive test date by
diagnosis CD4 cell count strata. Stratifying the analysis popu-
lation by CD4 cell count at HIV diagnosis and year of HIV
diagnosis, we were able to highlight the different approaches
for the treatment of asymptomatic HIV-positive patients
followed and characterize the impact on rates of ART treat-
ment initiation. We have shown a large reduction in antiret-
roviral treatment interruptions in more recent time periods,
as well as found no difference in the rate of major first-
line ART modification in participants diagnosed with ad-
vanced HIV compared to those diagnosed with a CD4 cell
count ]350 cells/mL.
A major strength of this analysis is the use of data linkage
methods. We matched patients from the AHOD with the NHR
and were able to obtain the best available information for
date of first positive HIV diagnosis and corresponding CD4
cell count for each participant in AHOD. We calculated the
proportion of patients diagnosed with advanced HIV in AHOD
(20%), which compares directly with the estimate provided
yearly from the NHR (1819%) [9]. Factors associated with
increased odds of late diagnosis with advanced HIV correlate
with previously published estimates. Several Australian stud-
ies have shown that sex, age, non-MSM modes of HIV ex-
posure, country of birth and regional setting are associated
with increased odds of advanced HIV diagnosis [1720].
Comparing our findings to similar epidemics concentrated
in men who have sex with men (MSM), we found notable
similarities of risk factors for advanced HIV presentation in-
cluded sex, age and overseas country of birth [2125].
Evaluating factors associated with increased risk of advanced
HIV diagnosis is important, especially in Australia where the
proportion of late presenters has remained stable over time. In
Australia, the estimate of persons infected with undiagnosed
HIV are 500011,500 [9,26]. The proportion of new diagnoses
likely attributed to transmission from undiagnosed HIV persons
is estimated to be 31% [12]. Our data corroborate and support
the strategy to further scale up targeted HIV testing (point-
of-care or standard) towards appropriate at-risk populations,
including those born or who frequently visit high prevalent
Figure 1. Time from first HIV-positive diagnosis to ART initiation stratified by year of diagnosis and CD4 cell count at HIV diagnosis.
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HIV countries, MSMs attending sexual health clinics in non-
state capital city settings and older agedMSM populations [27].
Of those AHOD participants diagnosed with advanced HIV
and regardless of year of diagnosis, the majority of patients
initiated antiretroviral therapy within three months of a first
positive HIV diagnosis. This finding is consistent with results
published from other similar international cohort studies
[23,2830]. Time to ART initiation within this group is un-
likely to get any shorter. It is has long been established that
initiating ART in immune-deplete patients as soon as possible
reduces AIDS-related illness and mortality. Considerations for
the delaying the timing ART in those that present with ad-
vanced HIV are largely based on individual circumstances.
Delaying the initiation of ART within this group might be in
part due to the management of prior comorbidities that
might complicate ART or negatively influence adherence (e.g.
mycobacterium tuberculosis) [31,32].
Evaluating the time from HIV diagnosis to time to antire-
troviral therapy initiation in non-advanced HIV diagnoses, our
results characterize broad changes. The management strate-
gies of initiating asymptomatic HIV-positive persons on treat-
ment have evolved over the time and this is reflected in our
data. In recent times, the so-called treatment pendulum
has swung back towards ART initiation rates comparable to
the ‘‘hit hard, hit early’’ treatment era [1]. Earlier treatment
initiation is partly gaining momentum due to better avail-
able antiretroviral formulations and reassuring results from
longer term ART exposure follow-up studies [33]. In addition,
evidence supporting suppressive ART reducing onwards trans-
mission risk at both an individual and population level is
Table 1. Analysis of population-patient characteristics by CD4 cell count at diagnosis
CD4 cell count at HIV diagnosis
Factor Level
CD4
B200 cells/mL N (%)
CD4
201350 cells/mL N (%)
CD4
350 cells/mL N (%)
Number of patients (Total n1202) 245 (20) 185 (15) 772 (65)
Year of cohort enrolment 19992004 135 (55) 82 (44) 280 (36)
20052009 72 (29) 56 (30) 279 (36)
20102012 38 (16) 47 (25) 213 (28)
Sex Female 14 (6) 16 (9) 54 (7)
Male 231 (94) 169 (91) 718 (93)
Age at cohort enrolment (years) B30 18 (7) 29 (16) 135 (17)
3040 69 (28) 58 (31) 293 (38)
4050 68 (28) 59 (32) 232 (30)
50 90 (37) 39 (21) 112 (15)
Mode of probable HIV exposure MSM 144 (59) 127 (69) 571 (74)
Heterosexual 70 (28) 45 (24) 146 (19)
IDU 12 (5) 5 (3) 30 (4)
Other 19 (8) 8 (4) 25 (3)
Continental region of birth Australia 135 (55) 110 (59) 502 (65)
New Zealand/Pacific Islander 4 (2) 5 (3) 21 (3)
Africa 9 (4) 6 (3) 8 (1)
Americas 6 (2) 2 (1) 9 (1)
Asia 22 (9) 14 (8) 42 (5)
Europe 20 (8) 14 (8) 41 (5)
Not reported 49 (20) 34 (18) 149 (19)
Hepatitis B SurAg (ever) Positive 10 (4) 7 (4) 18 (2)
Negative 199 (81) 148 (80) 598 (77)
Not reported 36 (15) 30 (16) 156 (20)
Hepatitis C antibody (ever) Positive 18 (7) 7 (4) 59 (8)
Negative 211 (86) 165 (89) 634 (82)
Not reported 16 (7) 13 (7) 79 (10)
Australian state capital city setting Capital city 162 (66) 126 (68) 565 (73)
Non-capital city 83 (34) 59 (32) 207 (27)
Primary care setting General practice 76 (31) 64 (35) 327 (42)
Hospital clinic 68 (28) 34 (18) 145 (19)
Sexual health clinic 101 (41) 87 (47) 300 (39)
MSMmen who have sex with men; IDUinjecting drug use.
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growing. In Australia it is now recommended to consider ART
initiation in asymptomatic patients regardless of CD4 cell
count [34]. Our data indicate that initiation of ART based on a
CD4 cell count threshold has been followed accordingly
throughout AHOD’s follow-up. These data should be informa-
tive for future evaluations of rates of ART initiation, especially
as treatment-as-prevention strategies are adopted and im-
plemented in Australia [35].
The hazard of switching a class of antiretroviral from the
initial ART regimen is similar by HIV presentation groups in
recent time periods. This result suggests that regardless
of CD4 cell count levels at ART initiation, the durability of
the first-line ART regimen is largely unaffected by the pre-
treatment HIV-positive diagnosis circumstances. The rate of
switching antiretroviral classes or making a major first-line
ART modification presented in this analysis are similar to
previous AHOD analysis [36,37] and comparable to data
published from other similar cohorts [38,39]. As a measure
of durability, the time to change of an antiretroviral class is
preferred over evaluating any antiretroviral modification,
as it is likely to correlate with a treatment failure associated
first-to-second line switches [36].
In the early era of ART, treatment regimens were cum-
bersome and complex leading to sub-optimal adherence. The
notion of a pill-break was largely considered for patients that
had responded well to initial therapy and achieved higher
CD4 cell counts. The Strategies for Management of Antire-
troviral Therapy (SMART) trial was designed to evaluate the
safety of structured treatment interruptions [40]. The trial
was terminated early due to patient safety concerns. It was
concluded that treatment interruptions increased the risk
of mortality, new AIDS- and non-AIDS-related illnesses. In the
Table 2. Factors associated with advanced HIV diagnosis: defined by CD4 cell count at diagnosis B200 cells/mL and or new AIDS
illness within six months of HIV diagnosis
Univariate model Multivariable model
Factor Level OR (95% CI) Pa aOR (95% CI) Pa
Sex Female 0.841 (0.46, 1.45) 0.48 0.50 (0.26, 0.98) 0.04
Male 1.00 (ref) 1.00 (ref)
Age at diagnosis (years) B30 1.00 (ref) B0.01 1.00 (ref) B0.01
3040 1.82 (1.05, 3.16) 1.73 (0.98, 3.05)
4050 2.21 (1.27, 3.83) 2.07 (1.16, 3.68)
50 5.73 (3.30, 9.94) 4.91 (2.74, 8.76)
Mode of probable HIV exposure MSM 1.00 (ref) B0.01 1.00 (ref) B0.01
Heterosexual 1.79 (1.29, 2.47) 2.04 (1.38, 3.02)
IDU 1.61 (0.82, 3.17) 1.96 (0.92, 4.18)
Other 2.70 (1.49, 4.88) 2.05 (1.08, 3.86)
Continental region of birth Australia 1.00 (ref) 0.02 1.00 (ref) B0.01
New Zealand/Pacific Islander 0.69 (0.25, 2.09) 0.72 (0.22, 2.20)
Africa 2.89 (1.23, 6.81) 3.87 (1.49, 10.08)
Americas 3.15 (1.18, 8.41) 2.60 (0.88, 7.70)
Asia 1.88 (1.12, 3.16) 2.57 (1.44, 4.58)
Europe 1.75 (1.02, 2.99) 1.78 (0.98, 3.21)
Not reported 1.27 (0.88, 1.82) 0.79 (0.53, 1.20)
Hepatitis B co-infection Positive 1.45 (0.69, 3.08) 0.14 1.41 (0.64, 3.15) 0.67
Negative 1.00 (ref) 1.00 (ref)
Not reported 0.73 (0.49, 1.07) 1.08 (0.64, 1.75)
Hepatitis C co-infection Positive 1.00 (0.58, 1.71) 0.27 0.99 (0.54, 1.81) 0.41
Negative 1.00 (ref) 1.00 (ref)
Not reported 0.64 (0.37, 1.10) 0.62 (0.31, 1.25)
Australian state capital city setting Capital city 1.00 (ref) 0.02 1.00 (ref) B0.01
Non-capital city 1.43 (1.06, 1.92) 2.40 (1.34, 4.31)
Primary care setting General practice 0.69 (0.50, 0.96) B0.01 1.36 (0.75, 2.45) B0.01
Hospital clinic 1.43 (1.00, 2.02) 2.88 (1.57, 5.30)
Sexual health clinic 1.00 (ref) 1.00 (ref)
Year of HIV diagnosis 19962000 1.00 (ref) B0.01 1.00 (ref) B0.01
20012006 0.46 (0.32, 0.65) 0.44 (0.31, 0.67)
20072012 0.72 (0.51, 1.02) 0.70 (0.48, 1.02)
aWald test for categorical level heterogeneity. MSMmen who have sex with men; IDUinjecting drug use.
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pre-SMART era treatment interruptions were observed in ap-
proximately one-in-ten patients per year. Importantly, in
recent time periods, our data show that treatment inter-
ruptions are now relatively uncommon (approximately 80%
reduction). Of those participants that did interrupt therapy,
our data shows a two-fold higher rate of treatment inter-
ruptions in those who initiated treatment with a higher CD4
cell count 350 cells/mL. This result likely corresponds to in-
terruptions being largely considered for patients with higher
CD4 cells counts and is consistent with other published
data, where higher CD4 cell count is associated with an in-
creased risk/rate of treatment interruption in the Asia-Pacific
region [41].
There are limitations to our analysis. First, of the 3603
AHOD patient records submitted for linkage with the NHR,
only 83% were matched exactly to records from the database.
Theoretically all AHOD participants should have a correspond-
ing record in the NHR as a positive HIV diagnosis is a notifiable
event to health authorities. Non-matched records are likely
due to the sensitivity of the data linkage key, which in this case
included the combination of 22 name code, date of birth,
sex and state/territory information. We speculate that the
majority of the non-matched cases are due to incorrect 22
name codes supplied to AHOD or the NHR. The 22 name
code is based on the participants first and last name at the
time of diagnosis or cohort enrolment. This identifier might
have changed or was incorrectly recorded at the time of
notification. In addition, the true name code might not have
been supplied due to the patients concern of disclosing
HIV status to government authorities. The data linkage could
be improved by utilizing fuzzy matching and or probabilistic
joining methods. However, the lack of unique patient iden-
tifiers in AHOD and NHR, might only incrementally improve
the results. Further exploration of these methods should be
considered for future 22 name code linkage projects.
Second, of the AHOD participants matched to records from
the NHR, n2982, 60% were excluded from the analy-
sis due to being diagnosed before the ART-era (n1383).
Table 3. Cox proportional hazarda of time to first ART treatment interruption (30 days) by HIV presentation category
Factor Interrupt/person-years (py) Rate (per 100 py) (95% CI) aHRa p
Year of ART initiation
19962000 83/784 10.6 (8.5, 13.0) 1.00 (ref) B0.001
20012006 57/670 8.5 (6.5, 10.9) 1.05 (0.72, 1.53)
20072012 13/741 1.8 (0.9, 3.0) 0.17 (0.09, 0.31)
HIV presentation statusb
adv. HIV diagnosis 36/799 4.5 (3.2, 6.2) 0.86 (0.49, 1.50) B0.001
CD4ART B350 cells/mL 24/596 4.0 (2.6, 5.9) 1.00 (ref)
CD4ART ]350 cells/mL 93/800 11.6 (9.5, 14.1) 1.96 (1.22, 3.20)
aModel adjusted for year of ART initiation, HIV presentation status, age, sex, HIV exposure, primary care clinic type; badv. HIV diagnosis: CD4 cell
count at HIVdiagnosis B200 cells/mL and or new AIDS illness within six months of diagnosis; CD4ART B350 cells/mL: CD4 cell count at HIVdiagnosis
350 cells/mL and CD4 cell count at ART initiationB350 cells/mL; CD4ART ]350 cells/mL: CD4 cell count at HIV diagnosis350 cells/mL and
CD4 cell count at ART initiation ]350 cells/mL.
Table 4. Cox proportional hazarda of time to switch to second line, by HIV presentation status
Factor Switch/person-years (py) Rate/100 py (95% CI) aHRa p
Year of ART initiation: 19962000
adv. HIV diagnosisb 46/317 14.5 (10.8, 18.9) 4.13 (1.28, 13.34) 0.01
CD4ART B350 cells/mL 3/87 3.4 (0.7, 9.7) 1.00 (ref)
CD4ART ]350 cells/mL 32/381 8.4 (5.8, 11.6) 2.46 (0.75, 8.07)
Year of ART initiation: 20012006
adv. HIV diagnosis 16/207 7.7 (4.5, 12.2) 0.73 (0.38, 1.40) 0.15
CD4ART B350 cells/mL 22/204 10.1 (6.9, 15.9) 1.00 (ref)
CD4ART ]350 cells/mL 16/314 5.1 (209, 8.1) 0.52 (0.27, 1.01)
Year of ART initiation: 20072012
adv. HIV diagnosis 13/167 7.8 (4.2, 12.9) 0.85 (0.43, 1.69) 0.22
CD4ART B350 cells/mL 24/249 9.6 (6.3, 14.0) 1.00 (ref)
CD4ART ]350 cells/mL 30/203 14.8 (10.1, 20.4) 1.43 (0.83, 2.45)
aModel adjusted for year of ART initiation, HIV presentation status, age, sex, HIV exposure, primary care clinic type; badv. HIV diagnosis: CD4 cell
count at HIVdiagnosis B200 cells/mL and or new AIDS illness within six months of diagnosis; CD4ART B350 cells/mL: CD4 cell count at HIVdiagnosis
350 cells/mL and CD4 cell count at ART initiation B350 cells/mL; CD4ART ]350 cells/mL: CD4 cell count at HIV diagnosis 350 cells/mL and
CD4 cell count at ART initiation ]350 cells/mL.
Wright ST et al. Journal of the International AIDS Society 2015, 18:19463
http://www.jiasociety.org/index.php/jias/article/view/19463 | http://dx.doi.org/10.7448/IAS.18.1.19463
7
The exclusion criterion was imposed to reduce survivor bias
in the time to ART initiation analysis. This was especially im-
portant for those diagnosed with advanced HIV. By restricting
data to the ART-era only, we selected a group of participants
where within each calendar year grouping, the same set
of treatment options were available to physicians at the time
of diagnosis. Selecting this population means that we have to
rely on retrospective treatment records for those that were
diagnosed (and initiated treatment) during 19961998. While
this sub-population is small relative to the rest of the analysis
cohort, we were unable to validate the completeness of their
treatment records.
Finally, it is likely that our selected analysis population
group is not fully representative of the entire HIV-positive
population in Australia. We believe that our data is largely
representative of HIV-positive persons receiving routine care.
However, we acknowledge that there might be selection-bias
towards persons who were not diagnosed with advanced HIV.
Our results are conditional on surviving after HIV diagnosis
long enough to be offered participation in AHOD. AHOD re-
quires informed consent and it is very likely that HIV-positive
persons who are diagnosed with advanced HIV are not con-
sidered for enrolment due to rapid disease progression or
death.
Conclusions
Recent HIV diagnoses are initiating therapy earlier. We note a
dramatic reduction in treatment interruptions and demon-
strate a stable rate of major first-line ART modifications in
AHOD. In the future as treatment-as-prevention strategies
scale up, more HIV diagnoses will be made across all levels
of immunosuppression. The data presented provide a good
indication that in recent times, HIV presentation status, and
by extension CD4 cell count at ART initiation, does not largely
influence the risk of treatment interruption or modification.
This is reassuring as both phenomena are essential for achiev-
ing and maintaining low levels of community viral load.
Authors’ affiliations
1The Kirby Institute, UNSW Australia, Sydney, Australia; 2Health Protection,
Communicable Diseases Branch, NSW Government Health, Sydney, Australia;
3Department of Medicine, Monash University, Melbourne, Australia; 4Department
of Infectious Diseases, Monash University, Melbourne, Australia; 5Infectious
Diseases, Monash Medical Centre, Melbourne, Australia; 6Brisbane Sexual Health
and HIV Services, Brisbane, Australia
Competing interests
The authors have no competing interest to disclose.
Authors’ contributions
All authors have read and approved the final version.
Australian HIV Observational Database contributors
Asterisks indicate steering committee members in 2013.
New South Wales: D Ellis, General Medical Practice, Coffs Harbour; M Bloch,
S Agrawal, T Vincent, Holdsworth House Medical Practice, Darlinghurst;
D Allen, JL Little, Holden Street Clinic, Gosford; D Smith, C Mincham, Lismore
Sexual Health & AIDS Services, Lismore; D Baker*, V Ieroklis, East Sydney
Doctors, Surry Hills; DJ Templeton*, CC O’Connor, S Phan, RPA Sexual Health
Clinic, Camperdown; E Jackson, K McCallum, Blue Mountains Sexual Health and
HIV Clinic, Katoomba; M Grotowski, S Taylor, Tamworth Sexual Health Service,
Tamworth; D Cooper, A Carr, F Lee, K Hesse, K Sinn, R Norris, St Vincent’s
Hospital, Darlinghurst; R Finlayson, I Prone, A Patel, Taylor Square Private Clinic,
Darlinghurst; R Varma, J Shakeshaft, Nepean Sexual Health and HIV Clinic,
Penrith; K Brown, C McGrath, V McGrath, S Halligan, Illawarra Sexual Health
Service, Warrawong; L Wray, P Read, H Lu, Sydney Sexual Health Centre,
Sydney; D Couldwell, Parramatta Sexual Health Clinic; DE Smith*, V Furner,
Albion Street Centre; Clinic 16  Royal North Shore Hospital, S Fernando,
Dubbo Sexual Health Centre, Dubbo; J Chuah*, Holdsworth House Medical
Practice, Byron Bay; J Watson*, National Association of People living with
HIV/AIDS; C Lawrence*, National Aboriginal Community Controlled Health
Organisation; B Mulhall*, Department of Public Health and Community
Medicine, University of Sydney; M Law*, K Petoumenos*, S Wright*,
H McManus*, C Bendall*, M Boyd*, The Kirby Institute, University of NSW.
Northern Territory: N Ryder, R Payne, Communicable Disease Centre, Royal
Darwin Hospital, Darwin. Queensland: D Russell, S Doyle-Adams, Cairns Sexual
Health Service, Cairns; D Sowden, K Taing, K McGill, Clinic 87, Sunshine Coast-
Wide Bay Health Service District, Nambour; D Orth, D Youds, Gladstone Road
Medical Centre, Highgate Hill; M Kelly, A Gibson, H Magon, Brisbane Sexual
Health and HIV Service, Brisbane; B Dickson*, CaraData. South Australia:
W Donohue, O’Brien Street General Practice, Adelaide. Victoria: R Moore,
S Edwards, R Liddle, P Locke, Northside Clinic, North Fitzroy; NJ Roth*, H Lau,
Prahran Market Clinic, South Yarra; T Read, J Silvers*, W Zeng, Melbourne
Sexual Health Centre, Melbourne; J Hoy*, K Watson*, M Bryant, S Price, The
Alfred Hospital, Melbourne; I Woolley, M Giles*, T Korman, J Williams*,
Monash Medical Centre, Clayton. Western Australia: D Nolan, J Robinson,
Department of Clinical Immunology, Royal Perth Hospital, Perth.
Coding of Death Form (CoDe) reviewers:
AHOD reviewers: D Sowden, J Hoy, L Wray, I Woolley, K Morwood, N Roth,
K Choong, CC O’Connor, MA Boyd.
TAHOD reviewers: PCK Li, MP Lee, S Vanar, S Faridah, A Kamarulzaman, JY Choi,
B Vannary, R Ditangco, K Tsukada, S Pujari, A Makane, OT Ng, AJ Sasisopin.
Acknowledgements
The Australian HIV Observational Database is funded as part of the Asia-Pacific
HIV Observational Database, a program of The Foundation for AIDS Research,
amfAR, and is supported in part by a grant from the U.S. National Institutes of
Health’s National Institute of Allergy and Infectious Diseases (NIAID) (Grant No.
U01-AI069907) and by unconditional grants fromMerck Sharp &Dohme; Gilead;
Bristol-Myers Squibb; Boehringer Ingelheim; Roche; Pfizer; GlaxoSmithKline;
Janssen-Cilag. The Kirby Institute is funded by the Australian Government
Department of Health and Ageing, and is affiliated with the Faculty of Medicine,
The University of New South Wales. The views expressed in this publication do
not necessarily represent the position of the Australian government.
References
1. Vella SS, Schwartländer BB, Sow SPS, Eholie SPS, Murphy RLR. The history of
antiretroviral therapy and of its implementation in resource-limited areas of
the world. AIDS. 2012;26:123141.
2. Anglemyer AT, Rutherford GW, Easterbrook PJ, Horvath T, Vitória M, Jan M,
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